The Drug Controller General of India (DCGI) has affirmed the utilization of hostile to viral medication Favipiravir for COVID-19 patients for confined use. The medication can be utilized distinctly if there should be an occurrence of a crisis and family assent of the patient is obligatory.

The term of the course is 14 days.

Glenmark Pharma is at present directing preliminaries for Favipiravir for use on coronavirus licenses. While the preliminaries are as yet in progress, the DCGI affirmed the medication in the wake of seeing empowering results.

The medication controller said observation for the initial 1,000 patients will be required in the wake of regulating Favipiravir to them.

While the medication is commonly utilized for flu around the world, Russia, China